Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Profit After Tax of -$16.4 million for Q1 2026, down 19.75% year-over-year from -$20.4 million in Q1 2025, and down 28.63% quarter-over-quarter from -$12.7 million in Q4 2025.
Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Profit After Tax data on file, last reported at -$16.4 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$16.4 million, down 19.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.0 million (down 39.43% YoY), and the FY2025 annual result was -$48.3 million, down 75.36% from the prior year.
- Profit After Tax declined to -$16.4 million in Q1 2026 per IKT's latest filing, from -$12.7 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$4.2 million in Q4 2023 and troughed at -$16.4 million in Q1 2026.
- A 5-year average of -$7.6 million and a median of -$5.0 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax climbed 15.13% in 2022, then sank 194.19% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$4.3 million in 2022, then advanced by 2.36% to -$4.2 million in 2023, then plunged by 190.4% to -$12.1 million in 2024, then fell by 4.96% to -$12.7 million in 2025, then retreated by 28.63% to -$16.4 million in 2026.
- Business Quant data shows IKT's Profit After Tax at -$16.4 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.74 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.38 Mn |
| Dec 31, 2025 | -12.73 Mn |
| Sep 30, 2025 | -11.93 Mn |
| Jun 30, 2025 | -9.92 Mn |
| Mar 31, 2025 | -13.68 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Sep 30, 2024 | -5.78 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.65 Mn |
| Dec 31, 2023 | -4.18 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -5.78 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Dec 31, 2022 | -4.28 Mn |
| Sep 30, 2022 | -4.49 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | -2.64 Mn |